hydroxyurea

P4, N=76, Active, not recruiting, Novartis Pharmaceuticals | Trial primary completion date: Jun 2026 --> Jan 2027

P3, N=340, Recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Sep 2026 --> Jul 2027

P2, N=60, Active, not recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd

P2, N=153, Not yet recruiting, RTOG Foundation, Inc. | Initiation date: Aug 2025 --> Nov 2025

P3, N=300, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Apr 2029 --> Mar 2028

Anagrelide (ANA), α-interferon (IFN) and ruxolitinib (Ruxo) increased, while hydroxyurea (HU) decreased platelet size. Anagrelide-induced abnormalities are reverted by RANTES addition. RANTES plasmatic levels and platelet RNA expression are decreased in anagrelide-treated vs untreated patients, suggesting in vitro findings could reflect anagrelide action in vivo.

ET can also lead to PHT, portal vein thrombosis, and esophageal varices. Clinicians should consider these possibilities when dealing with such patients.

Our findings suggest that ropeginterferon alfa-2b could be considered as a second-line treatment option for patients with essential thrombocythaemia and leukocytosis.

Dna2 mutants demonstrated significant sensitivity to replication stress induced by MMS, hydroxyurea, topotecan, and nitrogen mustard. Dna2lS/S1 mutants exhibited higher survival than Dna2lS/D2 upon exposure to topotecan and bleomycin, suggesting a possible helicase-specific role in damage response...These insights clarify the nuanced contributions of the nuclease and helicase domains of DNA2, suggesting potential domain-specific functions in genomic stability and repair mechanisms. This work provides a foundation that will enable future researchers to further dissect the complex roles of DNA2 in replication and repair pathways.

P3, N=320, Active, not recruiting, Geron Corporation | Recruiting --> Active, not recruiting

Case 6 experienced symptom relief after glucocorticoids and hydroxyurea treatment, followed by complete remission after chemotherapy with the cytarabine (20 mg q12 h × 14 days), idarubicin (5 mg on days 2-12 every other day), and G-CSF (adjusted based on blood counts) regimen. The remaining three patients demonstrated improvement after glucocorticoid treatment. Except for case 6, the other patients were still alive, with case 4 relapsing at 28 months after imatinib discontinuation and relieved after treatment re-initiation.

Discontinuation of hydroxyurea resolved symptoms permanently, and the patient was transitioned to ruxolitinib for management of the underlying disease. This case highlights the importance of recognizing hypersensitivity reactions during hydroxyurea therapy and implementing alternative strategies to optimize patient outcomes.